Literature DB >> 17067192

Utility measurement in healthcare: the things I never got to.

George W Torrance1.   

Abstract

The present article provides a brief historical background on the development of utility measurement and cost-utility analysis in healthcare. It then outlines a number of research ideas in this field that the author never got to. The first idea is extremely fundamental. Why is health economics the only application of economics that does not use the discipline of economics? And, more importantly, what discipline should it use? Research ideas are discussed to investigate precisely the underlying theory and axiom systems of both Paretian welfare economics and the decision-theoretical utility approach. Can the two approaches be integrated or modified in some appropriate way so that they better reflect the needs of the health field? The investigation is described both for the individual and societal levels. Constructing a 'Robinson Crusoe' society of only a few individuals with different health needs, preferences and willingness to pay is suggested as a method for gaining insight into the problem. The second idea concerns the interval property of utilities and, therefore, QALYs. It specifically concerns the important requirement that changes of equal magnitude anywhere on the utility scale, or alternatively on the QALY scale, should be equally desirable. Unfortunately, one of the original restrictions on utility theory states that such comparisons are not permitted by the theory. It is shown, in an important new finding, that while this restriction applies in a world of certainty, it does not in a world of uncertainty, such as healthcare. Further research is suggested to investigate this property under both certainty and uncertainty. Other research ideas that are described include: the development of a precise axiomatic basis for the time trade-off method; the investigation of chaining as a method of preference measurement with the standard gamble or time trade-off; the development and training of a representative panel of the general public to improve the completeness, coherence and consistency of measured preferences; and the investigation, using a model of a very small society, of the conflict between the patient perspective and the societal perspective regarding preferences. Finally, it is suggested that an important area of research, which the author never got to, would be to work closely with specific decision makers on specific decision problems, to help them formulate the problem, provide useful analyses, and to publish these as case studies to give the field a better understanding of the problems and the needs of decision makers.

Entities:  

Mesh:

Year:  2006        PMID: 17067192     DOI: 10.2165/00019053-200624110-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?

Authors:  Paul Dolan; Richard Edlin
Journal:  J Health Econ       Date:  2002-09       Impact factor: 3.883

2.  Economic foundations of cost-effectiveness analysis.

Authors:  A M Garber; C E Phelps
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

3.  Valuing health states: a comparison of methods.

Authors:  P Dolan; C Gudex; P Kind; A Williams
Journal:  J Health Econ       Date:  1996-04       Impact factor: 3.883

4.  Toward a utility theory foundation for health status index models.

Authors:  G W Torrance
Journal:  Health Serv Res       Date:  1976       Impact factor: 3.402

5.  A theoretical framework for TTO valuations of health.

Authors:  Ken Buckingham; Nancy Devlin
Journal:  Health Econ       Date:  2006-10       Impact factor: 3.046

Review 6.  Decision analysis: a progress report.

Authors:  J P Kassirer; A J Moskowitz; J Lau; S G Pauker
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

7.  Decision analysis: introductory lectures on choices under uncertainty. 1968.

Authors:  H Raiffa
Journal:  MD Comput       Date:  1993 Sep-Oct
  7 in total
  20 in total

1.  Why not real economics?

Authors:  F Reed Johnson
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Why not ask?: measuring patient preferences for healthcare decision making.

Authors:  F Reed Johnson
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

3.  Towards more consistent use of generic quality-of-life instruments.

Authors:  Mattias Neyt
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Better analysis for better decisions: facing up to the challenges.

Authors:  Michael F Drummond; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

Authors:  Scott Doyle; Andrew Lloyd; Lee Moore; Joshua Ray; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

7.  Utility estimation in chronic obstructive pulmonary disease: a preference for change?

Authors:  Jennifer Petrillo; Floortje van Nooten; Paul Jones; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

8.  Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?

Authors:  Wendy J Ungar
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

9.  Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.

Authors:  Richard H Osborne; Andrew Dalton; Judy Hertel; Rudolf Schrover; Dell Kingsford Smith
Journal:  Health Qual Life Outcomes       Date:  2012-04-02       Impact factor: 3.186

10.  Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.

Authors:  Salimah H Meghani; Christopher S Lee; Alexandra L Hanlon; Deborah W Bruner
Journal:  BMC Med Inform Decis Mak       Date:  2009-11-27       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.